Skip to main content

Celltrion Evaluating Crucell's Antibody, Protein Technology

NEW YORK (GenomeWeb News) – Celltrion will evaluate Crucell’s cell lines for use in its drug development services programs under a new licensing agreement, Crucell said today.
The non-exclusive agreement allows Celltrion to evaluate Crucell’s STAR technology, which is used in producing recombinant human antibodies and proteins, for its drug programs, Crucell said.
Crucell’s STAR technology contains genetic elements that enable stable gene expression that is used in making recombinant antibodies and proteins in mammalian cells. The Leiden, Netherlands-based firm said the technology can help increase the yields and lower the costs of antibody and protein production.
Celltrion offers services including cell line development and banking, process development, as well as technical, quality, and regulatory support services.
Financial terms of the agreement were not released.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.